Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach

Trial Profile

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Parkinson's disease; Tremor
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Aug 2017 Results (n=30) published in the Mayo Clinic Proceedings
    • 21 Apr 2016 Primary endpoint of Unified Parkinsons Disease Rating Scale (UPDRS) Tremor Scale has been met, according to results published in the 68th Annual Meeting of the American Academy of Neurology.
    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top